Protocol Ledger

NCT03944057 · Phase II · COMPLETED

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

Interventional Phase II clinical trial protocol NCT03944057 sponsored by Antengene in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-09-02 Enrollment: 82 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03944057
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)82 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03944057
Protocol FieldVerified Registry Value
NCT IdentifierNCT03944057
Consolidated Lead SponsorAntengene
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment82 participants (ACTUAL)
Registered Start Date2019-09-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI